This section includes information and resources about the Boehringer Ingelheim company: Press releases, related press kits, historical information, financial information and a collection of images and videos.
2014: Boehringer Ingelheim positioned for future growth with product launches
Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela® in Europe
Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals
35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Corporate Related Documents
Boehringer Ingelheim gives you the right to download images and to duplicate, publish and distribute them for your publishing activities as long as the photo bears the attribution "Image: Boehringer Ingelheim GmbH". Publication details and a voucher copy should be sent to us.
Any kind of changes or partial duplication, publication or distribution of the image are not permitted.
Boehringer Ingelheim GmbH as the headquarter is located in Ingelheim, the German town where the family-owned company was founded in 1885. Ingelheim is located 60 km west of Frankfurt, which is Germany's financial hub.
Ingelheim is also home of Boehringer Ingelheim Pharma GmbH & Co. KG, the company's German operating unit.
All details on
The ultimate parent company of the Boehringer Ingelheim Corporation is C.H. Boehringer Sohn. Boehringer Ingelheim GmbH, which is a subsidiary of C. H. Boehringer Sohn, is the central holding company for administrative purposes - the corporate central body which manages and directs the worldwide family of Boehringer Ingelheim companies and which delivers central services to all companies of the Corporation.
Boehringer Ingelheim GmbH, our Headquarters in Ingelheim/Germany,
Information needed about our 146 affiliated companies worldwide?
Prof.* Dr Dr Andreas Barner is Chairman of the Board. He is also Head of Corporate Board Divisions Human Resources and Research, Development and Medicine.
* Republic of Austria
The ultimate parent company of Boehringer Ingelheim is C.H. Boehringer Sohn.
Boehringer Ingelheim has 146 affiliated companies all over the world.
Whatever the degree of financial control, Boehringer Ingelheim's subsidiary companies are selfmanaging and have a large degree of operational independence. They rely on Boehringer Ingelheim GmbH for strategic services and investment and make a profit contribution to the Corporation.
The Boehringer Ingelheim Corporation has voting shares, not equity shares which can be traded or listed on any stock market or index. The Corporation has been a family-owned business for nearly 130 years.
"Value through Innovation" is our Corporate vision, our headline goal.
Value through Innovation has guided and will continue to guide our way of working together. It helps us build on our strength and make the most of our distinctive character, enabling us individually and collectively to achieve great success. Our vision is the driver of our culture and allows us to meet our future challenges ahead. Our vision is derived from our Leitbild which is the heart of who we are and why we exist as Boehringer Ingelheim. "Value through Innovation" means for us analysing and anticipating the value that customers will put on our products and services and then seeking to increase it by finding new and better ways of achieving the customer's goal.
Boehringer Ingelheim traces its history directly back to 1885, when Albert Boehringer set up his chemical factory making tartaric acid salts in Ingelheim, Germany.
Find out more about the company's history.
There was a separate pharma company called Boehringer Mannheim until 1998, when it was absorbed into the Swiss company Roche. It did indeed spring from the same origins.
In 1817, Christian Friedrich Boehringer helped to found a drug store and chemical laboratory in Stuttgart, which his son Christoph Heinrich moved to Mannheim in 1872. When C.H. Boehringer died in 1882, his elder son Ernst inherited the business in Mannheim, which was called C.F. Boehringer & Söhne.
Christoph Heinrich's younger son, Albert Boehringer, then set up his own chemical factory producing tartaric acid salts in Ingelheim in 1885. In 1892, he renamed this business "C.H. Boehringer Sohn" in memory of his father.
In 1892, Ernst Boehringer died, leaving the C.F. Boehringer business in the hands of his partner Dr Friedrich Engelhorn. Thus there were two pharmaceutical businesses bearing similar Boehringer names - one owned by the Boehringer family and one not.
This situation persisted until well after the World War II, when the two companies agreed to rename themselves Boehringer Ingelheim and Boehringer Mannheim in order to reduce the confusion somewhat.
In 2014, the Boehringer Ingelheim group of companies had more than 47,700 employees worldwide.
Average capacity of employees by region:
Boehringer Ingelheim is a research-driven company dedicated to researching and developing, manufacturing and marketing pharmaceuticals that improve health and quality of life.
Our businesses are Human Pharmaceuticals and Animal Health. We focus on innovative drugs and treatments that represent major therapeutic advances.
Biopharmaceuticals are medical drugs which are manufactured by biotechnology methods, having biological sources. At Boehringer Ingelheim for example, we use genetically engineered cell cultures and micro-organisms as production hosts. We hereby produce therapeutic proteins, fusion proteins, protein scaffolds, monoclonal antibodies, antibody mimetics and plasmid DNA. Biopharmaceuticals are large molecules and must usually be given by injection.
Find out more about our Biopharmaceuticals business.
Modern biotechnology is key for the discovery, development and production of innovative drugs to treat unmet medical needs. The importance of biotechnology has grown significantly since 1990, when less than 1% of all drugs were biopharmaceuticals, whereas today biopharmaceuticals represent 8%. The biopharmaceutical market overall is forecasted to grow at nearly 7% through to 2015, with monoclonal antibodies showing higher growth of 9%. Boehringer Ingelheim has established its reputation with a successful market introduction of 19 DNA-derived biopharmaceuticals produced for captive use and third party business. Four of these products are among the top 20 of the worldwide selling list. We continuously move ahead advancing with the benefit of our own research, through collaboration with research-oriented companies and our commercial partners, and working with leading academic networks.
Please follow the link for more details on Biopharmaceuticals.
Boehringer Ingelheim offers the entire production chain within its biopharmaceutical network which is located in Vienna (Austria), Biberach (Germany) and, since 2011, in Fremont (California), where we acquired a biopharmaceutical facility in the Bay area biotech cluster that complements our existing facilities.
At the Vienna site we produce therapeutics derived from bacterial and yeast fermentation and at the Biberach site we produce biopharmaceuticals derived from mammalian cell cultures.
All our production plants operate under cGMP and are approved by European, US, Canadian and Japanese authorities.
Pharmaceuticals Production produces Boehringer Ingelheim's own drugs in a globally coordinated production network as well as offering manufacturing services to our industrial customer according to their specific needs
Eight world-class state of the art manufacturing facilities, operated by highly experienced personnel, offer services in three continents. The proven track record of pharmaceuticals development and wide ranges of manufacturing technologies and packaging technologies in combination with the fully harmonised supply chain network offers many possibilities for the success of our customers.
All Pharmaceuticals Production's manufacturing facilities operate in strict compliance with current good manufacturing practice (cGMP) and are inspected and certified by regulatory agencies across the globe (FDA, EMEA, MHRA, ANVISA, ASEAN). In addition, our facilities are subject to regular inspections from Boehringer Ingelheim corporate auditors, ensuring a continuous improvement and a high level of cGMP awareness.
Animal Health is one of our two business areas. Although small relative to our Human Pharmaceuticals business, it is growing significantly above market and showing increasingly improved profitability. Boehringer Ingelheim's Animal Health business holds an international market share of 5.9%, putting it in the 6th position in the market. Our research-driven expertise and human pharmaceuticals excellence ensures to contribute to a safe and nutritious food supply and helps companion animals to live a longer and healthier life. We plan to focus more on preventative solutions and aim to become world market leader with our swine biologicals.
Boehringer Ingelheim's continued success is based on solid ground - our own R&D and our partner's excellence. Our alliances range from early stage research to development and marketing or co-promotion collaborations.
Partnering is essential part of our strategy to discover and market true innovations. Our strong pipeline complemented by our partnering activities is the basis for our dynamic growth above the market.
Within the Licensing Organisation Boehringer Ingelheim has two dedicated groups for the different functions within a partnering process:
Cross-functional Licensing Advisory Teams
Headed by Licensing Advisory Team Leaders with representatives from R&D, Medicine and Marketing responsible to evaluate opportunities. The Licensing Advisory Team Leaders have broad understanding of respective indication area, dedicated to identify opportunities of potential strategic interest. Immediate involvement of a broad range of disciplines ensures early alignment and rapid decision making within Boehringer Ingelheim.
Contract and Alliance Management
Global Team located in Germany, Japan and US responsible to negotiate and manage local and international partnering agreements. Rapid and transparent deal making processes are supported by dedicated professionals, empowered by senior management. Strong focus on business and contract-related matters ensures high level of commitment and experience concerning drafting, negotiation and management of agreements.
Our major Licensing focus is in our strategic therapeutic areas:
Our chapter Partnering informs about